Hitachi Chemical Advanced Therapeutics Solutions, LLC
Hitachi Chemical Advanced Therapeutics Solutions, LLC is the cell therapy manufacturing and development service platform of Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), a wholly owned subsidiary of Hitachi Chemical Company, Ltd. Leveraging nearly two decades of experience exclusively focused on the cell therapy industry, HCATS offers contract development and manufacturing organization (CDMO) services, at current Good Manufacturing Practices (cGMP) standards, through the PCT service platform, including clinical and commercial manufacturing, manufacturing development, and technology development. The service platform is the collection of know-how, resources, infrastructure, and technical capabilities used together to deliver cell therapy manufacturing development and manufacturing services. HCATS operates cGMP manufacturing and development facilities in the U.S. in Allendale, New Jersey (headquarters) and Mountain View, California. A facility in Yokohama, Japan has completed construction and another U.S. facility is planned for Allendale. European operations will begin in 2018. All facilities operate on our global, harmonized PCT service platform.